---
category: news
title: "Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second Quarter"
excerpt: "Kiromic achieves key milestone for this first-in-human Phase 1 clinical trial with a target derived by Kiromicâ€™s AI platform. HOUSTON-- ( BUSINESS WIRE )--Kiromic Biopharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) that is used to develop novel oncology therapeutics,"
publishedDateTime: 2021-05-24T15:55:00Z
originalUrl: "https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter"
webUrl: "https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter"
type: article

provider:
  name: Business Wire
  domain: businesswire.com

topics:
  - AI in Healthcare
  - AI

secured: "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;mS+N/sW+AbKvGwJeR2TAnQ=="
---

